C4 Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $35.9M | $35.6M | $20.8M | $31.1M | $45.8M |
| Research and development | $104.2M | $110.6M | $117.7M | $117.8M | $94.7M |
| Operating expenses | $151.2M | $155.2M | $159.8M | $160.6M | $127.9M |
| Operating income | -$115.2M | -$119.6M | -$139.0M | -$129.5M | -$82.1M |
| Pretax income | -$104.9M | -$105.2M | -$131.2M | -$128.2M | -$83.9M |
| Income tax expense | $121,000 | $131,000 | $1.3M | $0 | $0 |
| Net income | -$105.0M | -$105.3M | -$132.5M | -$128.2M | -$83.9M |
| Balance Sheet | |||||
| Cash and equivalents | $74.6M | $55.5M | $126.6M | $29.8M | $76.1M |
| Current assets | $258.1M | $257.8M | $271.2M | $287.6M | $325.7M |
| Total assets | $359.1M | $349.6M | $376.5M | $430.8M | $506.8M |
| Current liabilities | $33.0M | $45.2M | $42.8M | $44.5M | $51.2M |
| Total liabilities | $102.5M | $133.6M | $130.3M | $141.6M | $117.2M |
| Total debt | — | — | — | $12.5M | $12.5M |
| Stockholders' equity | $256.6M | $216.0M | $246.1M | $289.2M | $389.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$98.7M | -$65.2M | -$106.8M | -$105.9M | -$87.0M |
| Depreciation and amortization | $1.5M | $1.5M | $1.6M | $1.7M | $1.5M |
| Stock-based compensation | $19.1M | $29.7M | $27.2M | $30.0M | $21.5M |
| Capital expenditure | $607,000 | $180,000 | $1.7M | $5.5M | $1.3M |
| Free cash flow | -$99.3M | -$65.3M | -$108.5M | -$111.4M | -$88.2M |
| Share repurchases | $193,000 | $194,000 | $110,000 | $0 | — |
Shares outstanding 110.6M · Free float 87.1%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.